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Abstract
Objectives: To investigate the association between the extent of tapering tumor necrosis factor inhibitor (TNFi) and
the likelihood of achieving inactive disease in patients with axial spondyloarthritis (axSpA)
Methods: We analyzed 1575 1-year follow-up interval data of 776 axSpA patients treated with TNFi for more
than 1 year in a nationwide observational cohort. The decision on tapering TNFi was made by patients and
their physicians. We quantified TNFi used during interval as a dose quotient (DQ). The intervals were classified
into the heavy-tapering (DQ < 50), mild-tapering (DQ 50–99), and control groups (DQ = 100). Outcome
variables included achieving Ankylosing Spondylitis Disease Activity Score-inactive disease (ASDAS-ID) and
major clinical response of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50) in the follow-up visit.
The effects of TNFi tapering on the outcome were analyzed using the generalized estimating equation.
Results: At the baseline visit, 91.1% of the patients showed a high disease activity (ASDAS-CRP ≥ 2.1). DQ of
each interval was significantly influenced by the ASDAS-CRP measure in the prior follow-up (P < 0.001). ASDAS-
ID was observed in 42.3% of the intervals. A multivariable analysis showed that the likelihood of outcome achievement
was comparable between the control and mild-tapering groups, but significantly decreased in the heavy-tapering
group (vs. the control group, adjusted OR = 0.28, [95% CI, 0.08–0.94]). In contrast, the likelihood to achieve BASDAI50
response was not different among the groups. In the subgroup of patients who reached ASDAS-ID 1 year after TNFi
treatment (n = 327), ASDAS-ID was observed in 66.1% of the subsequent intervals, and only the mild-tapering group
showed a likelihood of target maintenance comparable with that of the control group (adjusted OR = 1.25 [0.41–3.80]).
This likelihood decreased with an increase in ASDAS-CRP.
Conclusion: Mild tapering of TNFi has efficacy comparable with that of the standard-dose treatment for ASDAS-ID
achievement in patients with axSpA.
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Background
The introduction of tumor necrosis factor inhibitor
(TNFi) in the treatment of axial spondyloarthritis (axSpA)
has considerably changed the outcome and prognosis of
the disease. The efficacy of long-term TNFi treatment has
been demonstrated by several randomized controlled trials
and large cohort studies [1–7]. However, the long-term
use of TNFi could increase economic burden on patients
and the risk of infection and possibly some kinds of malig-
nancy [7–9]. However, several patients continue TNFi
treatment despite maintaining persistent stable disease
activity because treatment discontinuation usually leads to
flares [10].
To overcome this problem, some studies have focused
on tapering TNFi in patients who maintain prolonged
low disease activity and showed that this strategy could
have comparable efficacy to that of the standard-dose
TNFi treatment at a lower cost [11–14]. Based on the
results of these studies, the European League Against
Rheumatism (EULAR) in its recent guideline recom-
mended that tapering TNFi can be considered for
patients who achieve sustained remission [15]. Further-
more, a recommendation by the International Task
Force emphasizes the “treat-to-target” strategy, accord-
ing to which achieving clinical remission or inactive dis-
ease is the optimal target for the best outcome [16].
However, it is not clear whether tapering TNFi could
also help to maintain the target. Moreover, information
regarding patients in whom tapering should be tried and
how it should be performed is limited, which is a hurdle
for the application of the tapering strategy in real-world
clinical settings.
Therefore, in this study, we aimed to (1) investigate
whether tapering of TNFi and its extent could influence
the likelihood of achieving inactive disease activity in
patients with axSpA in a nationwide prospective cohort
and (2) clarify the indication for tapering TNFi in real-
world clinical settings by assessing the clinical factors
that affect the probability of achieving inactive disease.
Methods
Study population
Data of the patients included in this study were collected
from the Korean College of Rheumatology Biologics
Registry (KOBIO) cohort, a nationwide cohort of patients
with inflammatory arthritis receiving biologic disease-
modifying antirheumatic drugs (bDMARDs) in daily clin-
ical practice since January 2013 (NCT01965132). By Janu-
ary 2017, 1462 patients with axSpA who started TNFi
treatment were consecutively enrolled from 47 tertiary re-
ferral centers in South Korea. A patient was enrolled when
he/she started a new TNFi treatment and was followed up
annually. If a patient stopped the TNFi treatment, the rea-
son and date of discontinuation were recorded. Because
KOBIO cohort is an observational cohort, treatment deci-
sion was made by patients and their physicians. However,
all the patients started TNFi treatment at the standard
dose. For data quality control, queries regarding incom-
plete data were regularly sent to each hospital for
clarification.
In this study, we excluded patients who missed follow-
up visits (n = 363) or those with missing information on
the TNFi dose (n = 15). In addition, patients treated with
TNFi for less than 1 year (n = 198) were excluded be-
cause it is less likely that they achieved the prolonged
stable disease activity required to be eligible for tapering
TNFi in real-world settings. In fact, patients in the
KOBIO cohort discontinued TNFi treatment due to in-
efficacy (n = 79), adverse drug reactions (n = 55), or poor
compliance/lost to follow-up (n = 40), supporting our
clinical assumption. A flow chart depicting patient inclu-
sion is presented in online Additional file 1: Figure S1.
The study was carried out in accordance with the
Declaration of Helsinki and was approved by the institu-
tional review boards of all participating hospitals.
Written informed consent was obtained from all the
patients.
Data collection
At the time of enrolment (defined as the baseline visit),
the baseline data of patients regarding demographics,
body mass index, smoking status (ever vs. never), previ-
ous treatment, HLA-B27 positivity, presence of definite
sacroiliitis (defined as bilateral sacroiliitis ≥ grade 2 or
unilateral sacroiliitis ≥ grade 3) in plain radiographs, and
baseline disease activity indices such as Ankylosing
Spondylitis Disease Activity Score (ASDAS), Bath Anky-
losing Spondylitis Disease Activity Index (BASDAI), and
Bath Ankylosing Spondylitis Functional Index (BASFI)
were collected. At each annual follow-up visit, the data
on disease activity indices, concomitant medications
(non-steroidal anti-inflammatory drugs and methotrex-
ate), and cumulative dose of TNFi were collected. The
TNFi dose during 1-year follow-up interval was quanti-
fied as dose quotient (DQ), calculated as (mean actual
dose/standard dose) × (standard − dosing interval/mean
actual dosing interval) × 100 [12]. The observation
period of this study was 3 years from the baseline visit or
the time to the discontinuation of TNFi starting at base-
line, whichever was first.
Change in DQ and outcomes
Because there is no universal recommendation regard-
ing tapering of TNFi in patients with axSpA, DQ of
the 1-year follow-up interval continuously changed
during the observation period (Additional file 1:
Figure S2). In addition, DQ could be influenced by
prior disease activity in real-world settings, and it was
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true for our data (P value in type 3 test of fixed
effect was < 0.001). This suggests that assessments on
TNFi tapering at the individual level cannot precisely
estimate the effect of tapering on the activity of
axSpA. Therefore, we performed a longitudinal ana-
lysis where each 1-year interval from all the included
patients was used as an observational unit. All 1-year
intervals were classified into one of the following
three groups according to their DQ (< 50, heavy-
tapering group; 50–99, mild-tapering group; and 100,
control group).
The primary outcome was achieving ASDAS-inactive
disease (ASDAS-ID, defined as ASDAS-CRP < 1.3) at the
follow-up visit. The secondary outcome included achiev-
ing BASDAI50 response criteria. In addition, the impact
of DQ on the likelihoods of achieving ASAS20/40,
ASDAS-low disease activity (ASDAS-LDA, defined as
1.3 ≤ASDAS-CRP < 2.1), BASDAI < 4, and C-reactive
protein (CRP) < 0.5 mg/dL at the follow-up visit was also
investigated.
Statistical analysis
All statistical analyses were based on observational
data, and missing data were not imputated. The rela-
tionship between dosing strategy of TNFi and longitu-
dinal disease activity was analyzed using generalized
estimating equations (GEEs) considering repeated
measurements for each patient [17]. An “exchange-
able” correlation matrix was selected based on the
correlation coefficients among the outcomes at each
interval. Univariable GEE was used to determine the
clinical factors associated with the outcomes in the 1-
year interval. If a factor showed a relevant association
with the outcome (P < 0.2), it was included as a co-
variate in the multivariable model.
We constructed two different multivariable models.
The first model (baseline model) included only covari-
ates measured at the baseline visit. The second model
(longitudinal model) included relevant covariates among
consecutively measured clinical factors such as disease
activity at each follow-up visit and concomitant medica-
tion during the 1-year follow-up interval. In addition,
because the effect of prior disease activity could differ
depending on the group, interaction between the group
and prior disease activity was also included if it was rele-
vant to the outcome in the univariable GEE. The fitness
of the model was assessed using quasi-likelihood under
the independence model criterion (QIC). For the sensi-
tivity analysis, we constructed another multivariable
model where all covariates with a clinically relevant
association with ASDAS-ID achievement were included.
In addition, the same GEE was used in the subgroup of
patients for whom complete follow-up data were avail-
able (n = 227). All statistical analyses were performed
using SPSS 20.0 software (Armonk, NY: IBM Corp.).




We analyzed 1575 1-year follow-up interval data of 776
patients. The number of intervals in the control, mild-
tapering, and heavy-tapering groups was 1091 (69.3%),
440 (27.9%), and 44 (2.8%), respectively. All patients
treated with subcutaneous agents (etanercept, adalimu-
mab, and golimumab) tapered their TNFi by prolonging
the dosing interval. Among the 176 intervals with
tapered infliximab treatment, 120 (68.2%) intervals
reduced the infusion dose and 67 (38.1%) increased the
dosing interval. Methotrexate (MTX) and sulfasalazine
were concomitantly administered in 38 (2.4%) and 21
(1.3%) intervals, respectively.
Throughout the observation period, 77 (9.9%) patients
stopped the TNFi treatment. Among them, 21 (2.7%)
and 16 (2.1%) patients discontinued the treatment due
to inefficacy and adverse events, respectively.
The baseline characteristics of the patients are sum-
marized in Table 1. Briefly, the mean (SD) age of
patients was 37.8 (12.5) years; 78% of them were male.
More than 90% of the patients were HLA-B27 positive.
Approximately 90% of the patients (681/776, 87.8%)
showed definite radiographic sacroiliitis in plain radio-
graphs and fulfilled the modified New York criteria for
ankylosing spondylitis (AS) [18]. The mean (SD)
ASDAS-CRP at baseline was 3.6 (1.1), and most patients
(91.1%) showed a high disease activity (ASDAS-CRP ≥
2.1).
Likelihood of outcome achievement during the follow-up
During the observation period, ASDAS-ID was observed
in 665 (42.3%) intervals. This proportion did not change
with the follow-up year. The likelihood of primary out-
come achievement was comparable between the control
and mild-tapering groups (41.2% and 46.3%, respect-
ively), but was markedly lower in the heavy-tapering
group (29.5%) (Fig. 1a). In contrast, the BASDAI50 re-
sponse criterion was fulfilled in a significantly higher
number of intervals than ASDAS-ID was (77.1%). It
remained unchanged with the follow-up time and was
comparable among the three groups (Fig. 1b).
Tapering of TNFi and achieving ASDAS-ID
The analysis using univariable GEE showed that older
age, obesity, ever-smoking status, negative HLA-B27,
and definite sacroiliitis in the baseline radiographs were
associated with a lower possibility of achieving ASDAS-
ID during the treatment. A higher ASDAS-CRP at the
baseline also decreased the likelihood of reaching
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ASDAS-ID. An increase in one unit of baseline ASDAS-
CRP reduced the odds by 23% (OR = 0.77 [95% confi-
dence interval (CI), 0.69–0.87]). Among the longitudinal
factors, the likelihood of achieving ASDAS-ID was sig-
nificantly influenced by ASDAS-CRP in the prior follow-
up visit (ASDASt − 1) (OR = 0.92 [95% CI, 0.86–0.98]).
Concomitant NSAID and sulfasalazine uses during the
follow-up interval were also associated with a lower
probability of achieving ASDAS-ID.
The analysis with multivariable GEE showed a com-
parable likelihood of reaching the target in the control
and mild-tapering groups. However, the likelihood was
significantly lower in the heavy-tapering group com-
pared with the control group. Both models showed con-
sistent results, but the QIC was relatively lower in the
longitudinal model (Table 2). We also performed the
longitudinal GEE model in which the difference of
ASDAS-CRP was used as an outcome variable. In this
analysis, reduction in ASDAS-CRP compared with its
baseline value in the control group was comparable to
that in the mild-tapering group, but was significantly
greater than the reduction in the heavy-tapering group
(adjusted β = 0.45, 95% CI 0.06–0.83).
Tapering of TNFi and fulfilling of BASDAI50 criteria
BASDAI50 response was achieved in 1207 (77.1%) of the
whole intervals. The analysis results of univariable GEE
in which BASDAI50 criterion fulfillment was used as an
outcome are presented in Table 3. Briefly, obesity, smok-
ing, and the presence of definite sacroiliitis in radio-
graphs, which impair the treatment response of TNFi,
were not associated with the outcome. On the contrary,
the criteria were more likely to be fulfilled among TNFi-
naïve patients. Of note, unlike the ASDAS-ID, there was
no significant difference in the likelihood of fulfilling the
BASDAI50 criteria among the three groups.
Tapering of TNFi and achieving other clinical outcomes
Proportion of 1-year intervals which achieved other clinical
outcomes such as ASDAS-LDA, ASAS20 and 40, BASDAI
< 4, and CRP < 0.5mg/dL during the observation is pre-
sented in Additional file 1: Figure S3. Briefly, ASDAS-LDA
was achieved in 512 (32.6%) 1-year intervals and the likeli-
hood for the target was not significantly different among
the three groups (33.2% in the control group, 30.4% in the
mild-tapering group, and 38.6% in the heavy-tapering
group). This result was not changed in the multivariable
GEE model where concomitant NSAID and sulfasalazine
uses were adjusted (Additional file 1: Table S1).
ASAS20 and 40 were achieved in 1141 (75.2%) and
1011 (66.6%) of the entire 1-year intervals, respectively.
In the multivariable analyses, likelihoods of achieving
ASAS20 and 40 were comparable between the control
and mild-tapering groups, but were significantly lower in
the heavy-tapering group. This result was consistent in
another multivariable GEE model where BASDAI < 4
and CRP < 0.5 mg/dL were selected as the outcome
(Additional file 1: Table S1).
Effect of TNFi tapering according to the disease activity at
the 1-year follow-up visit
As the likelihood of ASDAS-ID achievement in the 1-year
interval was low, we stratified all patients by the ASDAS-
CRP measured at the 1-year follow-up visit and analyzed
the probability of achieving ASDAS-ID at the subsequent
visits in each subgroup. Interestingly, this probability
increased as the ASDAS-CRP at the 1-year follow-up de-
creased (Fig. 2). In the subgroup of patients who achieved
ASDAS-ID at the 1-year follow-up (n = 327), the target was
successfully maintained in 66.1% of the subsequent
intervals. Multivariable analysis in this population showed
that the mild-tapering group, but not the heavy-tapering
group, had a likelihood of retaining the inactive disease
state comparable to that of the control group (Table 4). In
contrast, among patients who achieved ASDAS-LDA
Table 1 Baseline features of the patients in the KOBIO cohort at
the start of TNFi treatment
Clinical feature N = 776
Age, years, mean (SD) 37.8 (12.5)
Male gender, n (%) 605 (78.0)
Disease duration, years, mean (SD) 8.1 (6.0)
BMI, mean (SD) 23.4 (3.5)
Obesity, n (%) 228 (29.4)
Ever-smoker, n (%) 385 (49.6)
HLA-B27 positive, n (%)* 696 (90.7)
Ankylosing spondylitis, n (%) 681 (87.8)






ESR, mm/h, mean (SD)† 38.3 (30.5)
CRP, mg/dL, mean (SD)‡ 2.3 (2.8)
PGA (0–10), mean (SD) 6.2 (2.2)
BASDAI (0–10), mean (SD) 6.0 (1.9)
ASDAS-CRP, mean (SD) 3.6 (1.1)
BASFI, mean (SD) 3.5 (2.6)
AS ankylosing spondylitis, ASDAS Ankylosing Spondylitis Disease Activity Score,
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath
Ankylosing Spondylitis Functional Index, BMI body mass index, CRP C-reactive
protein, ESR erythrocyte sedimentation rate, HLA human leukocyte antigen,
PGA patient global assessment, SD standard deviation
*There were 9 missing data
†There were 16 missing data
‡There were 19 missing data
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(1.3 ≤ASDAS-CRP < 2.1) (n = 254), the probability of
achieving ASDAS-ID at the subsequent intervals was only
35.2%. Moreover, tapering of TNFi in this subgroup further
decreased the likelihood, irrespective of the extent of taper-
ing in the multivariable longitudinal model (adjusted OR =
0.53 [95% CI, 0.29–0.97]) (Additional file 1: Table S2). In
the last subgroup with ASDAS-CRP higher than 2.1 at the
1-year follow-up, only 11.6% (23/198) patients subsequently
achieved the target.
Sensitivity analysis
In the multivariable model in which all factors with clin-
ical relevance to the outcome were included, the result
was consistent with that drawn from the main analysis;
likelihood for achieving ASDAS-ID was comparable be-
tween the control and the mild-tapering groups but was
significantly lower in the heavy-tapering group (Add-
itional file 1: Table S3). In addition, the subgroup
analysis including patients who had completed a 3-year
observation period (n = 271) showed that ASDAS-ID
was achieved in 40.2% (274/681) of the intervals, which
was comparable to that of the entire population. The
multivariable model also showed consistent results. The
likelihood of achieving ASDAS-ID was not significantly
different between the control and mild-tapering groups,
but tended to decrease in the heavy-tapering group
(Additional file 1: Table S4).
Discussion
Although tapering of TNFi was first introduced in the
recent ASAS/EULAR guideline, its efficacy compared
with that of the standard-dose treatment has not been
thoroughly evaluated. Previous studies that investigated
the efficacy of the tapering strategy included a small
number of patients and had a relatively short observa-
tion period [11–14, 19]. Furthermore, indications for
tapering and the definition of clinical outcomes in these
studies were heterogeneous, making it difficult to inter-
pret the results. To the best of our knowledge, this is the
first large-scale study to investigate the efficacy of taper-
ing TNFi in real-world clinical settings, from the per-
spective of achieving ASDAS-ID as the optimal
treatment target.
In this study, ASDAS-ID was achieved in only 42.3%
of the entire 1-year intervals. Considering that patients
with TNFi treatment for less than 1 year were excluded,
the possibility of achieving the target could be lower in
real-world settings [20, 21]. The finding is also consist-
ent with the results of previous randomized controlled
trials where the probability of achieving ASDAS-ID with
TNFi treatment ranged between 16.1 and 36.5% [5, 22–
24]. In contrast, BASDAI50 criteria were fulfilled in ap-
proximately 80% of the intervals, indicating that it is a
more lenient target than ASDAS-ID. Interestingly, only
a small number of patients discontinued the TNFi treat-
ment due to loss of efficacy judged by their physician.
This result suggests that continuing TNFi treatment in
patients with axSpA is more influenced by a patient’s
subjective symptoms rather than stringent current
guidelines in real-world settings. It can also be attributed
to the fact that other bDMARDs such as IL-17A inhibi-
tors were not available in South Korea during the study
Fig. 1 Likelihood of achieving a ASDAS-inactive disease and b BASDAI50 response in the 1-year interval among the three groups during observation. ASDAS,
Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index
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period. In addition, because the second or third TNFi
usually shows a lower response rate than that by the first
one, physicians might have hesitated to change the treat-
ment if a patient had marginally high ASDAS with rela-
tively mild symptoms [25]. Therefore, more evidence
regarding the efficacy of alternative therapeutic options
after the failure of TNFi treatment is required for the
universal recommendation of the “treat-to-target”
strategy.
Our longitudinal analysis also demonstrated that the
standard dose of TNFi and mild tapering of TNFi were
associated with a comparable likelihood of achieving
ASDAS-ID in the 1-year interval, but the likelihood sig-
nificantly decreased in the heavy-tapering group. In con-
trast, the likelihood of fulfilling the BASDAI50 criteria
was not different among the three groups. Other clinical
outcomes such as ASAS20/40 and CRP < 0.5 mg/dL
showed the same trend with ASDAS-ID. Since ASAS20/
40, CRP, and ASDAS-CRP put more weight on inflam-
mation than BASDAI, it is likely that the discrepancy be-
tween the ASDAS-ID and BASDAI50 was derived from
the difference in inflammation control between the con-
trol and heavy-tapering group. This discrepancy again
suggests that a patient’s subjective symptom alone can-
not precisely estimate the activity of axSpA [26]. The re-
sults indicate that caution must be exerted while
tapering TNFi by more than 50% of the standard dose
even if a patient’s symptoms are well controlled. How-
ever, because the number of 1-year intervals in the
heavy-tapering group was small, this result should be
confirmed in the future.
The relatively low likelihood of achieving ASDAS-ID in
the follow-up intervals also suggests that non-selective ap-
plication of TNFi tapering in patients receiving TNFi
Table 2 Effect of tapering TNFi on the achievement of consecutive ASDAS-ID in the 1-year interval






OR (95% CI) (n = 767)
Baseline variable
Age, 10 years 0.87 (0.79–0.97) 0.91 (0.82–1.01) 0.92 (0.83–1.02)
Female sex 0.98 (0.73–1.30) ‡ ‡
Disease duration, 10 years 0.81 (0.66–1.002) 0.81 (0.65–1.02) 0.78 (0.61–0.98)
Obesity (BMI ≥ 25) 0.71 (0.54–0.93) 0.78 (0.59–1.04) 0.77 (0.58–1.01)
Ever-smokers 0.73 (0.57–0.93) 0.81 (0.63–1.04) 0.83 (0.64–1.08)
Positive HLA-B27 (vs. negative) 1.63 (1.03–2.56) 1.72 (1.09–2.71) 1.71 (1.08–2.73)
AS (vs. nr-axSpA) 0.66 (0.45–0.96) 0.71 (0.48–1.01) 0.72 (0.49–1.06)
TNFi naïve 0.98 (0.73–1.31) ‡ ‡
Baseline ASDAS-CRP, unit 0.77 (0.69–0.87) 0.76 (0.68–0.86) 0.78 (0.69–0.89)
Longitudinal variable
Follow-up time (vs. interval in the 1-year follow-up) Reference † ‡
Interval in the 2-year follow-up 0.98 (0.82–1.17) † ‡
Interval in the 3-year follow-up 1.06 (0.83–1.36) † ‡
ASDAS-CRPt − 1, unit 0.92 (0.86–0.98) † 0.95 (0.86–1.05)
Concomitant NSAID use during the interval 0.44 (0.35–0.56) † 0.45 (0.35–0.58)
Concomitant sulfasalazine use during the interval 0.31 (0.11–0.94) † 0.29 (0.09–0.90)
Concomitant MTX use during the interval 1.37 (0.76–2.44) † ‡
Group according to the interval DQ
Control group (DQ = 100) Reference Reference Reference
Mild-tapering group (50 ≤ DQ < 100) 1.21 (0.98–1.48) 1.19 (0.96–1.48) 0.89 (0.56–1.41)
Heavy-tapering group (DQ < 50) 0.44 (0.22–0.88) 0.43 (0.22–0.85) 0.27 (0.08–0.91)
QIC of the model 2059.054 2002.264
AS Ankylosing spondylitis, ASDAS Ankylosing Spondylitis Disease Activity Score, BMI body mass index, CI confidence interval, CRP C-reactive protein, DQ dose
quotient, HLA human leukocyte antigen, MTX methotrexate, nr-axSpA non-radiographic axial spondyloarthritis, NSAID non-steroidal anti-inflammatory drug, OR
odds ratio, QIC quasi-likelihood under the independence model criterion, TNFi tumor necrosis factor inhibitor
*The model was adjusted for the baseline clinical factors showing a relevant association (P < 0.2) with the outcome in the univariable model
†Not included in the model
‡Not included in the model because its association with the outcome was not relevant (P ≥ 0.2)
The model was adjusted for covariates in the baseline model and longitudinal factors with a relevant association (P < 0.2) with the outcome in the
univariable model
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treatment for more than 1 year is not appropriate to reach
the optimal goal. We found that patients who achieved
ASDAS-ID at the 1-year follow-up were highly likely to
maintain the target (66.1%) and that mild tapering of
TNFi did not influence this. It implies that achieving
ASDAS-ID after 1 year of TNFi treatment could be an ap-
propriate indication to consider tapering of TNFi. How-
ever, even in this subgroup, heavy tapering of TNFi was
associated with a low likelihood of maintaining the goal.
The limitations of this study include the following. First,
because it is an observational study, the results could have
been biased due to confounding by indication. For ex-
ample, data on the reason for tapering TNFi is lacking, so
it is uncertain whether it was performed strictly based on
the patient’s disease activity. We demonstrated that
tapering and its extent were considered to be at least par-
tially guided by patients’ disease activity. However, al-
though this interaction was adjusted in the longitudinal
model, some unmeasured confounders such as patient’s
compliance and economic status and physician preference
for tapering TNFi cannot be completely balanced. Regard-
ing the economic burden, however, all AS patients in
South Korea copay 10% of the cost of all prescribed medi-
cation (including TNFi) under the coverage of national
health insurance system [27]. Therefore, it is less likely
that the decision on tapering TNFi was driven by the fac-
tor. Second, this study did not show the effect of tapering
TNFi on maintaining ASDAS-ID for more than 1 year in
patients because the observational unit of this study was
not an individual patient. To clarify this important aspect,
Table 3 Effect of tapering TNFi on the achievement of consecutive BASDAI50 response in the 1-year interval
Univariable model
OR (95% CI) (n = 757–776)
Baseline model*
OR (95% CI) (n = 748)
Longitudinal model⁋
OR (95% CI) (n = 748)
Baseline variable
Age, 10 years 0.81 (0.72–0.91) 0.83 (0.72–0.95) 0.83 (0.73–0.94)
Female sex 0.80 (0.56–1.13) ‡ ‡
Disease duration, 10 years 0.69 (0.55–0.85) 0.89 (0.67–1.17) 0.89 (0.68–1.17)
Obesity (BMI ≥ 25) 0.88 (0.64–1.20) ‡ ‡
Ever-smokers 0.89 (0.67–1.19) ‡ ‡
Positive HLA-B27 (vs. negative) 1.69 (1.04–2.74) 1.50 (0.83–2.71) 1.47 (0.84–2.56)
AS (vs. nr-axSpA) 0.77 (0.48–1.21) ‡ ‡
TNFi naïve 1.75 (1.26–2.43) 1.49 (1.01–2.20) 1.44 (0.98–2.10)
Baseline BASDAI, unit 1.64 (1.52–1.78) 1.61 (1.48–1.75) 1.93 (1.72–2.16)
Baseline CRP, mg/dL 1.21 (1.10–1.33) 1.13 (1.04–1.23) 1.13 (1.04–1.22)
Longitudinal variable
Follow-up time (vs. interval in the 1-year follow-up) Reference † Reference
Interval in the 2-year follow-up 0.99 (0.81–1.20) † 0.52 (0.35–0.77)
Interval in the 3-year follow-up 0.60 (0.46–0.79) † 0.27 (0.16–0.45)
BASDAIt − 1, unit 1.12 (1.08–1.15) † 0.78 (0.70–0.89)
CRPt − 1, mg/dL 1.11 (1.04–1.18) † 1.01 (0.94–1.08)
Concomitant NSAID use during the interval 0.80 (0.60–1.07) † ‡
Concomitant sulfasalazine use during the interval 0.69 (0.32–1.47) † ‡
Concomitant MTX use during the interval 1.04 (0.49–2.24) † ‡
Group according to the interval DQ
Control group (DQ = 100) Reference Reference Reference
Mild-tapering group (50 ≤ DQ < 100) 0.93 (0.73–1.20) 0.94 (0.70–1.26) 1.03 (0.61–1.74)
Heavy-tapering group (DQ < 50) 0.80 (0.43–1.51) 0.82 (0.34–1.97) 1.09 (0.26–4.55)
QIC of the model 1367.597 1317.502
AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Activity Index, BMI body mass index, CI confidence interval, CRP C-reactive protein, DQ dose
quotient, HLA human leukocyte antigen, MTX methotrexate, nr-axSpA non-radiographic axial spondyloarthritis, NSAID non-steroidal anti-inflammatory drug, OR
odds ratio, QIC quasi-likelihood under the independence model criterion, TNFi tumor necrosis factor inhibitor
*The model was adjusted for baseline clinical factors showing a relevant association (P < 0.2) with the outcome in the univariable model
†Not included in the model
‡Not included in the model because its association with the outcome was not relevant (P ≥ 0.2)
The model was adjusted for covariates in the baseline model and longitudinal factors with a relevant association (P < 0.2) with the outcome in the
univariable model
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a randomized controlled trial with a well-designed proto-
col will be required. Third, because KOBIO being a re-
cently established ongoing registry, there was relatively a
small number of patients, especially in the heavy-tapering
group, who completed the 3-year follow-up visit. Finally,
the incidence of adverse drug reactions related to TNFi
and its relationship to tapering were not thoroughly inves-
tigated in this study.
Conclusions
In summary, our study showed that mild tapering of TNFi
had efficacy comparable with that of the standard-dose treat-
ment in maintaining the optimal target in patients with
axSpA who reached ASDAS-ID 1 year after TNFi treatment.
Although this result should be confirmed with randomized
studies in the future, it provides important real-world evi-
dence for universal recommendation of the tapering strategy.
Fig. 2 Likelihood of achieving ASDAS-inactive disease in the subsequent intervals according to the ASDAS-CRP measured at the 1-year follow-up.
ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; CRP, C-reactive protein
Table 4 Effect of tapering DQ on maintaining ASDAS-ID in patients who achieved ASDAS-ID at 1-year follow-up
Number (%) of 1-year intervals
maintained the ASDAS-ID
Univariable model
OR (95% CI) (n = 230–236)
Baseline model*
OR (95% CI) (n = 236)
Longitudinal model†
OR (95% CI) (n = 236)
Group according to the interval DQ
Control group (DQ = 100) 122 (65.6) Reference Reference Reference
Mild-tapering group (50 ≤ DQ < 100) 84 (69.4) 1.16 (0.70–1.45) 1.22 (0.73–2.04) 1.25 (0.41–3.80)
Heavy-tapering group (DQ < 50) 10 (50.0) 0.58 (0.23–1.45) 0.57 (0.23–1.41) 0.19 (0.05–0.74)
QIC of the model 422.244 413.739 407.520
ASDAS Ankylosing Spondylitis Disease Activity Score, CI confidence interval, DQ dose quotient, OR odds ratio, QIC quasi-likelihood under the independence
model criterion
*The model was adjusted for age, sex, and baseline ASDAS-CRP
†The model was adjusted for covariates in the baseline model, ASDASt − 1, concomitant NSAID, and interaction between ASDASt − 1 and group
Park et al. Arthritis Research & Therapy          (2019) 21:163 Page 8 of 10
Additional file
Additional file 1: Figure S1. Flow chart of inclusion. Figure S2.
Dynamic changes in dose quotient (DQ) of TNFi in included patients
during the follow-up (time level). Figure S3. Proportion of 1-year intervals
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the achievement of various outcomes in 1-year intervals. Table S2. Effect
of tapering DQ on maintaining ASDAS-ID in subsequent 1-year intervals
in the subgroup of patients who showed ASDAS-low disease activity
(1.3≤ ASDAS-CRP < 2.1) at 1-year follow-up (n = 254). Table S3. Multivari-
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as covariates. Table S4. Effect of tapered DQ on the achievement of con-
secutive ASDAS-ID in the subgroup of patients who completed 3-year
follow-up. (DOCX 1150 kb)
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